Physician profile
Jimmy Peter Cassis
NPI 1508156357
$2,135.70
in general payments reported to CMS, 2019-2025
10 companies · $326 in 2025
The $326 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $141 · 2022: $346 · 2023: $873 · 2024: $450 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,648.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $691.26 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $483.92 | 2022-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $260.13 | 2021-2023 | Vivitrol |
| Janssen Pharmaceuticals, INC | $234.68 | 2022-2025 | Invega Sustenna, Spravato |
| Neurocrine Biosciences, INC. | $185.54 | 2024-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $123.78 | 2023-2025 | Uzedy |
| Axsome Therapeutics, INC. | $58.26 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $52.50 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.93 | 2023 | |
| Indivior INC. | $21.70 | 2023 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jimmy Cassis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.